guest ::
| Home > Publications database > Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial. > print |
| Home > Publications database > Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial. > print |
| 001 | 128067 | ||
| 005 | 20240228145532.0 | ||
| 024 | 7 | _ | |a 10.1038/bmt.2017.91 |2 doi |
| 024 | 7 | _ | |a pmid:28504661 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC5543255 |2 pmc |
| 024 | 7 | _ | |a 0268-3369 |2 ISSN |
| 024 | 7 | _ | |a 0951-3078 |2 ISSN |
| 024 | 7 | _ | |a 1476-5365 |2 ISSN |
| 024 | 7 | _ | |a altmetric:20165397 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2017-04089 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Huhn, S. |b 0 |
| 245 | _ | _ | |a Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial. |
| 260 | _ | _ | |a London |c 2017 |b Nature Publishing Group55086 |
| 264 | _ | 1 | |3 online |2 Crossref |b Springer Science and Business Media LLC |c 2017-05-15 |
| 264 | _ | 1 | |3 print |2 Crossref |b Springer Science and Business Media LLC |c 2017-08-01 |
| 264 | _ | 1 | |3 print |2 Crossref |b Springer Science and Business Media LLC |c 2017-08-01 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1510664536_10758 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 536 | _ | _ | |a 319H - Addenda (POF3-319H) |0 G:(DE-HGF)POF3-319H |c POF3-319H |f POF III |x 0 |
| 542 | _ | _ | |i 2017-05-15 |2 Crossref |u https://creativecommons.org/licenses/by-nc-nd/4.0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Weinhold, N. |b 1 |
| 700 | 1 | _ | |a Nickel, J. |b 2 |
| 700 | 1 | _ | |a Pritsch, M. |b 3 |
| 700 | 1 | _ | |a Hielscher, T. |0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f |b 4 |
| 700 | 1 | _ | |a Hummel, M. |0 P:(DE-He78)fae4f3c76bbbd2fc21dd920b46945d42 |b 5 |
| 700 | 1 | _ | |a Bertsch, U. |b 6 |
| 700 | 1 | _ | |a Huegle-Doerr, B. |b 7 |
| 700 | 1 | _ | |a Vogel, M. |b 8 |
| 700 | 1 | _ | |a Angermund, R. |b 9 |
| 700 | 1 | _ | |a Hänel, M. |b 10 |
| 700 | 1 | _ | |a Salwender, H. J. |b 11 |
| 700 | 1 | _ | |a Weisel, K. |b 12 |
| 700 | 1 | _ | |a Dürig, J. |b 13 |
| 700 | 1 | _ | |a Görner, M. |b 14 |
| 700 | 1 | _ | |a Kirchner, H. |b 15 |
| 700 | 1 | _ | |a Peter, N. |b 16 |
| 700 | 1 | _ | |a Graeven, U. |b 17 |
| 700 | 1 | _ | |a Lordick, F. |b 18 |
| 700 | 1 | _ | |a Hoffmann, M. |b 19 |
| 700 | 1 | _ | |a Reimer, P. |b 20 |
| 700 | 1 | _ | |a Blau, I. W. |b 21 |
| 700 | 1 | _ | |a Jauch, A. |b 22 |
| 700 | 1 | _ | |a Dembowsky, K. |b 23 |
| 700 | 1 | _ | |a Möhler, T. |b 24 |
| 700 | 1 | _ | |a Wuchter, P. |b 25 |
| 700 | 1 | _ | |a Goldschmidt, H. |0 P:(DE-He78)a1aa959d47e3e026abe157a8adf24b96 |b 26 |u dkfz |
| 773 | 1 | 8 | |a 10.1038/bmt.2017.91 |b Springer Science and Business Media LLC |d 2017-05-15 |n 8 |p 1194-1198 |3 journal-article |2 Crossref |t Bone Marrow Transplantation |v 52 |y 2017 |x 0268-3369 |
| 773 | _ | _ | |a 10.1038/bmt.2017.91 |g Vol. 52, no. 8, p. 1194 - 1198 |0 PERI:(DE-600)2004030-1 |n 8 |p 1194-1198 |t Bone marrow transplantation |v 52 |y 2017 |x 0268-3369 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:128067 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)fae4f3c76bbbd2fc21dd920b46945d42 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 26 |6 P:(DE-He78)a1aa959d47e3e026abe157a8adf24b96 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-319H |2 G:(DE-HGF)POF3-300 |v Addenda |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BONE MARROW TRANSPL : 2014 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l Biostatistik |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)V964-20160331 |k V964 |l NCT-KliHD |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a I:(DE-He78)V964-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| 999 | C | 5 | |a 10.1038/leu.2013.313 |9 -- missing cx lookup -- |1 SK Kumar |p 1122 - |2 Crossref |u Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122–1128. |t Leukemia |v 28 |y 2014 |
| 999 | C | 5 | |a 10.1016/S1470-2045(16)30206-6 |9 -- missing cx lookup -- |1 S Kumar |p e328 - |2 Crossref |u Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17: e328–e346. |t Lancet Oncol |v 17 |y 2016 |
| 999 | C | 5 | |a 10.1182/blood.V126.23.191.191 |9 -- missing cx lookup -- |1 H Avet-Loiseau |p 191 - |2 Crossref |u Avet-Loiseau H, Corre J, Lauwers-Cances V, Chretien M-L, Robillard N, Leleu X et al. Evaluation of minimal residual disease (MRD) by next generation sequencing (NGS) is highly predictive of progression free survival in the IFM/DFCI 2009 Trial. Blood 2015; 126: 191. |t Blood |v 126 |y 2015 |
| 999 | C | 5 | |a 10.1200/JCO.2012.46.2119 |9 -- missing cx lookup -- |1 AC Rawstron |p 2540 - |2 Crossref |u Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 2013; 31: 2540–2547. |t J Clin Oncol |v 31 |y 2013 |
| 999 | C | 5 | |a 10.1038/bmt.2015.164 |9 -- missing cx lookup -- |1 AM Sherrod |p 2 - |2 Crossref |u Sherrod AM, Hari P, Mosse CA, Walker RC, Cornell RF . Minimal residual disease testing after stem cell transplantation for multiple myeloma. Bone Marrow Transplant 2016; 51: 2–12. |t Bone Marrow Transplant |v 51 |y 2016 |
| 999 | C | 5 | |a 10.1038/leu.2015.80 |9 -- missing cx lookup -- |1 EK Mai |p 1721 - |2 Crossref |u Mai EK, Bertsch U, Durig J, Kunz C, Haenel M, Blau IW et al. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia 2015; 29: 1721–1729. |t Leukemia |v 29 |y 2015 |
| 999 | C | 5 | |a 10.1200/JCO.2011.39.6820 |9 -- missing cx lookup -- |1 P Sonneveld |p 2946 - |2 Crossref |u Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 2012; 30: 2946–2955. |t J Clin Oncol |v 30 |y 2012 |
| 999 | C | 5 | |a 10.1023/A:1008286803199 |9 -- missing cx lookup -- |1 FW Cremer |p 633 - |2 Crossref |u Cremer FW, Kiel K, Wallmeier M, Goldschmidt H, Moos M . A quantitative PCR assay for the detection of low amounts of malignant cells in multiple myeloma. Ann Oncol 1997; 8: 633–636. |t Ann Oncol |v 8 |y 1997 |
| 999 | C | 5 | |a 10.1016/j.jim.2009.06.008 |9 -- missing cx lookup -- |1 Y Hu |p 70 - |2 Crossref |u Hu Y, Smyth GK . ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009; 347: 70–78. |t J Immunol Methods |v 347 |y 2009 |
| 999 | C | 5 | |2 Crossref |u Helsel DR. Nondetects and Data Analysis: Statistics for Censored Environmental Data. John Wiley and Sons: Hoboken, NJ, USA, 2005.. |
| 999 | C | 5 | |a 10.1200/JCO.2005.04.242 |9 -- missing cx lookup -- |1 PR Greipp |p 3412 - |2 Crossref |u Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420. |t J Clin Oncol |v 23 |y 2005 |
| 999 | C | 5 | |a 10.3324/haematol.2009.016436 |9 -- missing cx lookup -- |1 K Neben |p 1150 - |2 Crossref |u Neben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A et al. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 2010; 95: 1150–1157. |t Haematologica |v 95 |y 2010 |
| 999 | C | 5 | |a 10.1182/blood-2011-09-379164 |9 -- missing cx lookup -- |1 K Neben |p 940 - |2 Crossref |u Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012; 119: 940–948. |t Blood |v 119 |y 2012 |
| 999 | C | 5 | |a 10.1002/cyto.b.21273 |9 -- missing cx lookup -- |1 O Landgren |p 14 - |2 Crossref |u Landgren O, Owen RG . Better therapy requires better response evaluation: paving the way for minimal residual disease testing for every myeloma patient. Cytometry B Clin Cytom 2016; 90: 14–20. |t Cytometry B Clin Cytom |v 90 |y 2016 |
| 999 | C | 5 | |a 10.1038/nrclinonc.2014.239 |9 -- missing cx lookup -- |1 S Mailankody |p 286 - |2 Crossref |u Mailankody S, Korde N, Lesokhin AM, Lendvai N, Hassoun H, Stetler-Stevenson M et al. Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev Clin Oncol 2015; 12: 286–295. |t Nat Rev Clin Oncol |v 12 |y 2015 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|